Despite early indicators of artemisinin resistance in Rwanda, ACTs continue to cure malaria
Programme offers a collaborative platform where participants can freely share data and ideas to accelerate innovation.
for the radical cure of relapsing P. vivax malaria in more than 60 years, approved by the US FDA and Australian TGA
working to help defeat malaria – part of an overall network of 400 partners in 50 countries
delivered to 13 countries in 2019, enough to protect more than 20 million children
160 different drugs or compounds with known or predicted activity against SARS-COV2 and other coronaviruses, available free of charge.
The MMV at a glance highlights our unique partnership model, the growth of our portfolio and the increasing impact of our access work.
Next-generation researchers in malaria and other neglected diseases discuss their work and aspirations.